- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02998671
Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne
A Randomized, Subject and Investigator Blinded, Placebo-controlled, Multi-center Study in Parallel Groups to Assess the Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Bonn, Germany, 53111
- Novartis Investigative Site
-
Frankfurt, Germany, 60590
- Novartis Investigative Site
-
Muenster, Germany, 48149
- Novartis Investigative Site
-
Pommelsbrunn, Germany, 91224
- Novartis Investigative Site
-
-
-
-
-
Bergen op Zoom, Netherlands, 4624 VT
- Novartis Investigative Site
-
Groningen, Netherlands, 9713 GZ
- Novartis Investigative Site
-
Leiden, Netherlands, 2333 CL
- Novartis Investigative Site
-
-
-
-
California
-
Culver City, California, United States, 90230
- Novartis Investigative Site
-
Sacramento, California, United States, 95819
- Novartis Investigative Site
-
-
Texas
-
Austin, Texas, United States, 78759
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female subjects aged 18 to 45 years of age included, and otherwise in good health as determined by medical history, physical examination, vital signs, ECGs and laboratory tests at screening.
- Body weight between 50 and 120 kg, inclusive at screening.
- Patients with papulo-pustular acne vulgaris with between 25 and 100 facial inflammatory lesions (papules, pustules and nodules), and presence of non-inflammatory lesions (open and closed comedones) in the face at screening and baseline, who have failed systemic therapy for inflammatory acne.
- No more than 5 facial inflammatory nodules at screening and baseline.
- Investigator's Global assessment (IGA) score of at least moderate (3) acne severity on the face at screening and baseline.
Exclusion Criteria:
- Appropriate wash out periods are required for investigational drugs, any oral/systemic treatment for acne, systemic or lesional injected (for acne) corticosteroids or systemic immunomodulators, any systemic hormonal treatments, previous treatment with biologics, oral retinoids (in particular isotretinoin) and any topical anti-acne treatment.
- Use of facial medium depth chemical peels (excluding home regimens) within 3 months prior to baseline.
- Any live vaccines (this includes nasal-spray flu vaccine) starting from 6 weeks before baseline.
- Any other forms of acne
- Any severe, progressive or uncontrolled medical or psychiatric condition or other factors at randomization that in the judgment of the investigator prevents the patient from participating in the study.
- History of hypersensitivity or allergy to the investigational compound/compound class being used in this study.
- Active systemic infections (other than common cold) during the 2 weeks prior to baseline.
- History of severe systemic Candida infections or evidence of Candidiasis in the 2 weeks prior to baseline.
- Evidence of active tuberculosis at screening. All patients will be tested for tuberculosis status using a blood test (QuantiFERON®-TB (Tuberculosis) Gold In-Tube). Patients with evidence of tuberculosis may enter the trial afteradequate treatment has been started according to local regulations.
- Patients with known active Crohn's disease
- History of immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result at screening.
- A positive Hepatitis B surface antigen or Hepatitis C test result at screening
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive Human chorionic gonadotropin (HCG) laboratory test.
- WOCBP, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 13 weeks after stopping medication.
Other protocol-defined inclusion/exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1: CJM112 high dose
CJM112 high dose in treatment period 1; CJM112 high dose in extension period 2
|
|
Experimental: Group 2: CJM112 low dose
CJM112 low dose in treatment period 1; CJM112 low dose in extension period 2
|
|
Placebo Comparator: Group 3: Placebo, CJM112 low dose or high dose
Placebo in treatment period 1; CJM112 low dose or CJM112 high dose in extension period 2
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total Inflammatory Facial Lesion Count at Day 85
Time Frame: Day 85
|
Total inflammatory facial lesion count was the total count of papules, pustules and nodules assessed at day 85
|
Day 85
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number and Severity of Adverse Events in Period 1
Time Frame: Day 1 to Day 85
|
Frequency and severity of adverse events in Period 1
|
Day 1 to Day 85
|
Number and Severity of Adverse Events in Period 2
Time Frame: Day 86 to Day 260
|
Frequency and severity of adverse events in Period 2
|
Day 86 to Day 260
|
Pharmacokinetics (PK): Serum Trough Concentrations of CJM112 in Period 1
Time Frame: Day 1, Day 29, Day 57 and Day 85
|
Pharmacokinetics (PK): Serum trough concentrations of CJM112.
Concentrations below the lower limit of quantification were reported as 0.
|
Day 1, Day 29, Day 57 and Day 85
|
Pharmacokinetics (PK): Serum Trough Concentrations of CJM112 in Period 2
Time Frame: Day 85, Day 113, Day 141 and Day 169
|
Pharmacokinetics (PK): Serum trough concentrations of CJM112.
Concentrations below the lower limit of quantification were reported as 0.
|
Day 85, Day 113, Day 141 and Day 169
|
Number of Patients With Clinically Significant Abnormal Hematology Laboratory Parameters
Time Frame: 38 Weeks
|
Abnormalities were considered clinically significant by the Investigator if they could impact the study conduct or safety of the subjects.
|
38 Weeks
|
Number of Patients With Clinically Significant Abnormal Clinical Chemistry Laboratory Parameters Parameters
Time Frame: 38 Weeks
|
Abnormalities were considered clinically significant by the Investigator if they could impact the study conduct or safety of the subjects.
|
38 Weeks
|
Number of Patients With Clinically Significant Abnormal Urinalysis Laboratory Parameters
Time Frame: 38 Weeks
|
Abnormalities were considered clinically significant by the Investigator if they could impact the study conduct or safety of the subjects.
|
38 Weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CCJM112X2203
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acne Vulgaris
-
Galderma R&DCompletedSevere Acne VulgarisUnited States, Canada, Puerto Rico
-
Sebacia, Inc.CompletedInflammatory Acne VulgarisUnited States
-
Nexgen Dermatologics, Inc.Unknown
-
InMode MD Ltd.Active, not recruitingInflammatory Acne VulgarisUnited States
-
PollogenLumenis Be Ltd.Not yet recruitingModerate to Severe Acne Vulgaris
-
Boston PharmaceuticalsCompletedModerate to Severe Acne VulgarisUnited States, Canada
-
Bispebjerg HospitalCompleted
-
Actavis Mid-Atlantic LLCCompletedMILD TO SEVERE ACNE VULGARISIndia
-
Assiut UniversityCompleted
-
Zagazig UniversityCompletedAcne Vulgaris Superficial Mixed Comedonal and InflammatoryEgypt
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States